Kiora Pharmaceuticals (KPRX) Competitors $2.73 +0.11 (+4.20%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.68 -0.05 (-1.83%) As of 08/22/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KPRX vs. ITRM, OKUR, MRSN, XLO, KLTO, ESLA, RNXT, SCYX, CLSD, and AKTXShould you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include Iterum Therapeutics (ITRM), OnKure Therapeutics (OKUR), Mersana Therapeutics (MRSN), Xilio Therapeutics (XLO), Klotho Neurosciences (KLTO), Estrella Immunopharma (ESLA), RenovoRx (RNXT), SCYNEXIS (SCYX), Clearside Biomedical (CLSD), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical products" industry. Kiora Pharmaceuticals vs. Its Competitors Iterum Therapeutics OnKure Therapeutics Mersana Therapeutics Xilio Therapeutics Klotho Neurosciences Estrella Immunopharma RenovoRx SCYNEXIS Clearside Biomedical Akari Therapeutics Kiora Pharmaceuticals (NASDAQ:KPRX) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk. Is KPRX or ITRM more profitable? Iterum Therapeutics' return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Kiora PharmaceuticalsN/A -47.17% -34.00% Iterum Therapeutics N/A N/A -65.01% Which has better earnings & valuation, KPRX or ITRM? Kiora Pharmaceuticals has higher revenue and earnings than Iterum Therapeutics. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiora Pharmaceuticals$16.02M0.58$3.60M-$2.91-0.94Iterum TherapeuticsN/AN/A-$24.77M-$0.85-0.88 Does the media prefer KPRX or ITRM? In the previous week, Iterum Therapeutics had 3 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 3 mentions for Iterum Therapeutics and 0 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 0.00 equaled Iterum Therapeutics'average media sentiment score. Company Overall Sentiment Kiora Pharmaceuticals Neutral Iterum Therapeutics Neutral Do insiders and institutionals have more ownership in KPRX or ITRM? 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 0.1% of Kiora Pharmaceuticals shares are owned by insiders. Comparatively, 2.4% of Iterum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, KPRX or ITRM? Kiora Pharmaceuticals has a beta of -0.64, meaning that its share price is 164% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.85, meaning that its share price is 185% more volatile than the S&P 500. Do analysts rate KPRX or ITRM? Kiora Pharmaceuticals presently has a consensus target price of $10.00, suggesting a potential upside of 266.30%. Iterum Therapeutics has a consensus target price of $9.00, suggesting a potential upside of 1,109.68%. Given Iterum Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Iterum Therapeutics is more favorable than Kiora Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryIterum Therapeutics beats Kiora Pharmaceuticals on 8 of the 12 factors compared between the two stocks. Get Kiora Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPRX vs. The Competition Export to ExcelMetricKiora PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.37M$2.53B$5.81B$9.76BDividend YieldN/A1.67%4.39%4.06%P/E Ratio-0.9422.9031.3626.05Price / Sales0.58516.56387.8788.42Price / Cash2.20179.1038.0259.36Price / Book0.425.939.536.60Net Income$3.60M$31.83M$3.26B$265.65M7 Day Performance-6.83%1.89%2.14%2.00%1 Month Performance-10.49%1.62%3.22%0.46%1 Year Performance-27.59%9.25%30.18%18.88% Kiora Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPRXKiora Pharmaceuticals2.7575 of 5 stars$2.73+4.2%$10.00+266.3%-27.6%$9.37M$16.02M-0.9410ITRMIterum Therapeutics1.8299 of 5 stars$0.82-6.2%$9.00+1,002.9%-38.5%$36.62MN/A-0.9610OKUROnKure Therapeutics3.2016 of 5 stars$2.66-4.9%$32.33+1,114.2%N/A$36.34MN/A-0.56N/ANews CoverageMRSNMersana Therapeutics4.2157 of 5 stars$7.28-1.4%$56.60+677.5%-80.1%$36.33M$34.77M-0.50150XLOXilio Therapeutics2.7145 of 5 stars$0.70-1.3%$3.00+329.8%-22.1%$36.18M$6.34M-0.9270KLTOKlotho NeurosciencesN/A$0.77-2.1%N/AN/A$35.46MN/A-2.14N/AEarnings ReportGap UpESLAEstrella Immunopharma2.2607 of 5 stars$0.94+2.7%$16.00+1,611.2%-26.8%$34.66MN/A-3.60N/ARNXTRenovoRx2.893 of 5 stars$0.94+0.1%$7.25+670.5%-6.9%$34.41M$40K-2.486News CoverageAnalyst UpgradeShort Interest ↓Analyst RevisionSCYXSCYNEXIS1.1457 of 5 stars$0.80-0.2%N/A-50.8%$33.58M$3.75M-2.0060News CoverageAnalyst RevisionCLSDClearside Biomedical1.8557 of 5 stars$0.41-3.7%$4.20+924.4%-60.1%$32.19M$4.17M-1.1130AKTXAkari Therapeutics2.3337 of 5 stars$1.00flat$5.00+400.0%-76.0%$32.18MN/A0.009 Related Companies and Tools Related Companies Iterum Therapeutics Competitors OnKure Therapeutics Competitors Mersana Therapeutics Competitors Xilio Therapeutics Competitors Klotho Neurosciences Competitors Estrella Immunopharma Competitors RenovoRx Competitors SCYNEXIS Competitors Clearside Biomedical Competitors Akari Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPRX) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access